Bharat Biotech And Serum Institute Set To Manufacture Doses For Intranasal COVID-19 Vaccines

Bharat Biotech and Serum Institute of India are going to manufacture two intranasal COVID-19 vaccines. While Bharat Biotech is producing one billion doses for Washington University School of Medicine's adenoviral intranasal vaccine candidate, Serum Institute of India has startedmanufacturing US-based Codagenix's CDX-005, another intranasal vaccine. 

Both the Indian pharmaceuticals have two vaccines under trials in the country, already. Covaxin, Bharat Biotech's indigenious COVID-19 vaccine has completed Phase I trials. Serum Institute of India is conducting Phase III trials for Astrazeneca's Oxford trials in India.